For Immediate Release <\/p>\n
Chicago, IL \u2013 August 26, 2026 \u2013 Today, Zacks Investment Ideas features like Bloom Energy BE, Micron MU, NVIDIA NVDA, UBS UBS and Moderna MRNA <\/p>\n
3 Reasons AI Stocks Are Primed for a Rebound <\/p>\n
Although AI stocks have been highly volatile over the past two months, they likely aren’t finished moving higher. Below are three reasons why: <\/p>\n
The Situational Awareness Saga Is Over <\/p>\n
Last month, momentum stocks, particularly AI stocks, suffered one their worst drawdowns in history. Situational Awareness, one of the newest and hottest hedge funds, got caught on the wrong side of long trades in leading AI-related stocks like Bloom Energy and Micron with extreme leverage. The fund, up a staggering 439% in the first half of the year due to 4x leverage, dropped nearly 70% in July, leading to a record $35 billion in losses. <\/p>\n
To stay solvent after steep losses, Situational Awareness sold its entire public book to Wall Street kingpin Citadel for over $4 billion. A handful of days later, Citadel sold its Situational Awareness positions for a massive profit. The Citadel sales likely explain the recent volatility and weakness in AI stocks. <\/p>\n
NVIDIA Earnings Loom <\/p>\n
Zacks Rank #2 (Buy) stock\u00a0NVIDIA\u00a0is the largest company in the world and the most important in the leading artificial intelligence industry. Wednesday, NVIDIA will report earnings after the market close. In recent quarters, NVIDIA has released earnings growth that is unprecedented for a company of its size.\u00a0 <\/p>\n
However, according to the latest hyperscaler capital expenditure estimates, NVIDIA’s growth curve may gain even more momentum. CAPEX spending is expected to surge to more than $1 trillion over the next few years. According to UBS, CAPEX spending will surge 60% by 2028. That’s good news for NVIDIA, which captures roughly 39% of every hyperscaler dollar spent. <\/p>\n
Meanwhile, despite its high double-digit top-and bottom-line growth rate, NVIDIA remains surprisingly cheap with a P\/E ratio of just 35.70x. <\/p>\n
AI is a Gamechanger for the Biotech Sector <\/p>\n
Until recently, most investors AI mostly benefited AI-centric stocks. That said, AI’s positive impact is finally being seen across sectors. Last week, Moderna announced that its personalized melanoma cancer therapy succeeded in a 1,137-patient Phase 3 trial. However, the Phase 3 win is much more than a biotech story. The Moderna data shows that AI computation allowed Moderna to personalize the medicine, making it far more effective than legacy biotech drugs. Moderna shares jumped 176% on the news. The Moderna news is likely just the tip of the iceberg. <\/p>\n
Bottom Line <\/p>\n
While recent market turbulence tested momentum, the washout of extreme leverage combined with surging multi-year infrastructure spending and real-world biotech breakthroughs means the AI rally is far from over. <\/p>\n
Why Haven’t You Looked at Zacks’ Top Stocks? <\/p>\n
Since 2000, our top stock-picking strategies have blown away the S&P’s +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. <\/p>\n
Today you can access their live picks without cost or obligation. <\/p>\n
See Stocks Free >> <\/p>\n
Media Contact <\/p>\n
Zacks Investment Research <\/p>\n
800-767-3771 ext. 9339 <\/p>\n
support@zacks.com <\/p>\n
https:\/\/www.zacks.com <\/p>\n
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed\u00a0that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and\u00a0is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https:\/\/www.zacks.com\/performance\u00a0for information about the performance numbers displayed in this press release. <\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a> <\/p>\n UBS Group AG (UBS) : Free Stock Analysis Report<\/a> <\/p>\n Micron Technology, Inc. (MU) : Free Stock Analysis Report<\/a> <\/p>\n NVIDIA Corporation (NVDA) : Free Stock Analysis Report<\/a> <\/p>\n Moderna, Inc. (MRNA) : Free Stock Analysis Report<\/a> <\/p>\n Bloom Energy Corporation (BE) : Free Stock Analysis Report<\/a> <\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a> <\/p>\n